OTS

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Friday, October 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Wyss Institute, Harvard–MIT Program in Health Sciences and Technology, MIT, OTS, Harvard Medical School, CSO, Manuscript, Engineering, Outline of health sciences, Therapy, Wyss Institute for Biologically Inspired Engineering, RNA, George Church, Doctor of Philosophy, Oligonucleotide, Enzyme, Harvard University, Poster, NTS Sessions 1–4, Wyss, Fine chemical

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

EQS-News: Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society

Retrieved on: 
Tuesday, October 17, 2023
Oligonucleotide, TLR9, OTS, Kinetics, LNA, ASO, Asos, Patient, Poster, Infection, Fine chemical

Munich/Martinsried, Germany, October 17, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus platform, will present data showcasing the continuous progress and innovation generated by the Company’s cutting-edge LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society (OTS).

Key Points: 
  • Munich/Martinsried, Germany, October 17, 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus platform, will present data showcasing the continuous progress and innovation generated by the Company’s cutting-edge LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society (OTS).
  • The meeting will be held October 22-25, 2023 in Barcelona, Spain.
  • This pathway, which has the physiological function to rapidly recognize infections and initiate an early immune response, can be activated by therapeutic oligonucleotides.
  • TLR9 activity of oligonucleotides depends on their sequence, but chemical modifications, such as LNA modification, also impact their immunostimulatory potential.

General Dynamics Ordnance and Tactical Systems Awarded $218 Million to Expand Artillery Production

Retrieved on: 
Monday, October 2, 2023
Weapon, OTS, Assemble, General Dynamics, Hazardous waste, GD, Multimedia, Marine Corps Tactical Systems Support Activity, Pack, Engineering, United States Department of the Army, LAP, NYSE, Arms industry, United States Army

ST. PETERSBURG, Fla., Oct. 2, 2023 /PRNewswire/ -- General Dynamics Ordnance and Tactical Systems (OTS), a business unit of General Dynamics (NYSE: GD), announced today it was awarded a $218 million initial task order for 155mm M1128 Load, Assemble, and Pack (LAP). The task order, awarded under a $974 million multiyear firm-fixed-price U.S. Army contract awarded to OTS and another company, includes funding for M1128 facilitization and production at OTS's operations in Camden, Arkansas.

Key Points: 
  • ST. PETERSBURG, Fla., Oct. 2, 2023 /PRNewswire/ -- General Dynamics Ordnance and Tactical Systems (OTS), a business unit of General Dynamics (NYSE: GD), announced today it was awarded a $218 million initial task order for 155mm M1128 Load, Assemble, and Pack (LAP).
  • The task order, awarded under a $974 million multiyear firm-fixed-price U.S. Army contract awarded to OTS and another company, includes funding for M1128 facilitization and production at OTS's operations in Camden, Arkansas.
  • OTS was awarded a similar contract in February 2023 for M795 LAP facilitization of 20,000 rounds per month.
  • General Dynamics Ordnance and Tactical Systems is a global leader in the design, engineering and production of munitions, energetics, weapons, armaments, and missile subsystems around the world.

A Truth and Reconciliation Commitment Statement from Canada’s Leading Occupational Therapy Organizations Signals a New Path Forward

Retrieved on: 
Friday, September 29, 2023
OT, Complicity, United Nations, OTS, United Nations Declaration on the Rights of Indigenous Peoples Act (Canada), Truth and Reconciliation Commission (South Africa), Truth and Reconciliation Commission of Canada, Final Report of the Task Force on Combating Terrorist and Foreign Fighter Travel, Commitment, Rights, Indigenous peoples, OTA, Employment, Occupational therapy, UNDRIP, Organization, Dive (Belgian band), Person-centered therapy, Student, MMIWG, TRC, Trauma, Woman, Nursing, Truth

Ottawa, ON, Sept. 29, 2023 (GLOBE NEWSWIRE) -- On September 30, 2023, Canada’s leading occupational therapy organizations reaffirmed their dedication to Indigenous Peoples in Canada through addressing the Truth and Reconciliation Commission (TRC) of Canada’s Calls to Action with the announcement of a joint Occupational Therapy TRC Commitment Statement.

Key Points: 
  • Ottawa, ON, Sept. 29, 2023 (GLOBE NEWSWIRE) -- On September 30, 2023, Canada’s leading occupational therapy organizations reaffirmed their dedication to Indigenous Peoples in Canada through addressing the Truth and Reconciliation Commission (TRC) of Canada’s Calls to Action with the announcement of a joint Occupational Therapy TRC Commitment Statement.
  • The document has been developed with leadership from the Occupational Therapy TRC Task Force’s Co-Chairs and Métis occupational therapists, Angie Phenix and Kaarina Valavaara, along with invited allies and members of the Boards of Directors of the Canadian Association of Occupational Therapists (CAOT), the Canadian Occupational Therapy Foundation (COTF), the Alliance of Canadian Occupational Therapy Professional Associations (ACOTPA), the Association of Canadian Occupational Therapy Regulatory Organizations (ACOTRO), and the Association of Canadian Occupational Therapy University Programs (ACOTUP).
  • The organizations acknowledge that “transforming our colonial reality must be a responsibility shared by all Canadians” and the Commitment Statement represents “beginning steps in embracing this shared responsibility” with acknowledgement of the harmful colonizing narratives, policies, and practices in the Canadian occupational therapy profession and a commitment to change within their respective mandates.
  • The Co-Chairs call upon all occupational therapists (OTs), occupational therapist assistants (OTAs), students, and other readers of the Commitment Statement to take responsibility and action to support the respective leadership organizations.

Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Technology, Manufacturing, Health, General Health, Pharmaceutical, Medical Devices, Research, Other Manufacturing, Software, Science, GMP, DNA, LVV, OTS, Transfection, Doctor of Philosophy, AAV, EDT, ATMP, CDMO, Patient, CRL, NYSE, Vaccine, Pharmaceutical industry, MD

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™ .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™ .
  • The addition of Lentivation follows the launch of Charles River’s OTS LVV packaging and AAV pHelper plasmids, and eXpDNA™ plasmid manufacturing platform, aimed at supporting both LVV-based and AAV-based gene therapy programs.
  • Lentivation also complements the nAAVigation™ platform announced previously, further bolstering Charles River’s cell and gene therapy manufacturing capabilities.
  • The proven platform builds on Charles River’s established capabilities and processes, fine-tuned over decades spent successfully supporting advanced therapy clients.” - Beth Tebeau, Site Director, Rockville, MD, Charles River

Applications Now Open for New COTF Gowan Health Indigenous Scholarships for Occupational Therapy Studies

Retrieved on: 
Thursday, September 21, 2023
Linda, Partnership, OTS, Yoshitaka Ota, Occupational therapy, Person-centered therapy, Student, System, Nursing, Employment

Ottawa, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The Canadian Occupational Therapists Foundation (COTF) and the Canadian Association of Occupational Therapists (CAOT) have partnered with Gowan Consulting to announce the New Gowan Health Indigenous Scholarship to support Indigenous people pursuing graduate studies in occupational therapy.

Key Points: 
  • Ottawa, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The Canadian Occupational Therapists Foundation (COTF) and the Canadian Association of Occupational Therapists (CAOT) have partnered with Gowan Consulting to announce the New Gowan Health Indigenous Scholarship to support Indigenous people pursuing graduate studies in occupational therapy.
  • This scholarship program showcases the commitment to empowering the next generation of Indigenous Occupational Therapists.
  • “Special thanks to Gowan Consulting, CAOT & the COTF Board of Directors for partnering so more Indigenous students will receive the support they need to achieve their Occupational Therapy aspirations.”
    The Gowan Health Indigenous Scholarship aims to support Indigenous academics in attaining their graduate degree in the Occupational Therapy Master’s program within Canada.
  • “The Gowan Health Indigenous Scholarship is an example of an amazing initiative that makes all of us at CAOT incredibly proud to partner with COTF,” says Phillip Wendt, CAOT President.

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Retrieved on: 
Tuesday, September 19, 2023
Surgery, Health, Medical Devices, Ankle, Nicorette, OTS, Surgeon, University, Lapidus, American Orthopaedic Foot and Ankle Society, SYK, Convention, Foot, Expert, Utility, Multimedia, Stryker Corporation, National Primate Research Exhibition Hall, Patient, MIS, NYSE, Dentistry, Cotton

The system will debut at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Louisville, Ky., Sept. 20-23 (booth no.

Key Points: 
  • The system will debut at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Louisville, Ky., Sept. 20-23 (booth no.
  • View the full release here: https://www.businesswire.com/news/home/20230919818115/en/
    Stryker's PROstep® MIS Lapidus is a new internal fixation system intended for treating bunions using a minimally invasive surgical reduction of hallux valgus deformity and subsequent fusion of the first metatarsal cuneiform joint.
  • The new technology features MIS joint preparation, triplanar reduction, and a three-screw construct designed to create a tension band for biomechanical stability.
  • Stryker is now the exclusive distributor of the OTS that contains the wedge implants for osteotomies of the foot.

OTS, Caltrans Launch “Safety is Sharing. Safety is Caring.” Media Campaign to Promote Bicycle and Pedestrian Safety

Retrieved on: 
Tuesday, September 12, 2023
Public Policy, Government, State, Local, Marketing, Other Transport, Communications, Public Safety, Public Transport, Transport, OTS, Travel, Road traffic safety, Education, Culture, PSAS, Safety, California Department, Eye, California Highway Patrol, Governors Highway Safety Association, CHP, SCAG, Automobile Club of Southern California, Death, Walking, California Office of Environmental Health Hazard Assessment, AAA, Southern California Association of Governments, Radio, City, Weather, Crash, Pedestrian, Injury, Road, California Department of Transportation

The California Office of Traffic Safety (OTS) and California Department of Transportation (Caltrans) today announced the launch of a new “Safety is Sharing.

Key Points: 
  • The California Office of Traffic Safety (OTS) and California Department of Transportation (Caltrans) today announced the launch of a new “Safety is Sharing.
  • As California and the country continue to experience increased bicycle and pedestrian deaths , the campaign reinforces the principle that safety is a shared responsibility involving all road users.
  • By focusing on education, awareness and collaborative efforts, the campaign seeks to create a safer environment for everyone who uses California's roadways.
  • Safety is Caring.” campaign features a new video in English and Spanish on digital platforms, audio messages on radio and streaming services, and digital billboards.

Aurisco's Busy Business Development

Retrieved on: 
Tuesday, August 22, 2023
Business development, OTS, Drug delivery, USFDA, API, Medication, Science, N-Acetylgalactosamine, DDL, Oligonucleotide, Conference, Fine chemical

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Aurisco Pharmaceutical Co., Ltd (Aurisco), a science-based, USFDA inspected CRDMO and cGMP generic API manufacturer, announced today that members of its senior management are scheduled to participate and exhibit, until the end of the year, in the following upcoming conferences and tradeshows:

Key Points: 
  • Aurisco Pharmaceutical will attend and exhibit at a series of conferences and tradeshows in the US and Europe.
  • Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development.
  • Customers want to expand their collaborations with Aurisco, and we will meet them where the best science and innovation is presented".
  • Rafael Antunes, Vice-President for Business Development in Europe, added further "While we are expanding our pipeline with generic peptides, GalNAc and oligonucleotides, we're also signing CRDMO contracts for new modalities with innovators.

Aurisco's Busy Business Development

Retrieved on: 
Tuesday, August 22, 2023
Business development, OTS, Drug delivery, USFDA, API, Medication, Science, N-Acetylgalactosamine, DDL, Oligonucleotide, Conference, Fine chemical

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Aurisco Pharmaceutical Co., Ltd (Aurisco), a science-based, USFDA inspected CRDMO and cGMP generic API manufacturer, announced today that members of its senior management are scheduled to participate and exhibit, until the end of the year, in the following upcoming conferences and tradeshows:

Key Points: 
  • Aurisco Pharmaceutical will attend and exhibit at a series of conferences and tradeshows in the US and Europe.
  • Join our team at the above events to discuss your challenges in oligonucleotide, peptide and small molecule development.
  • Customers want to expand their collaborations with Aurisco, and we will meet them where the best science and innovation is presented".
  • Rafael Antunes, Vice-President for Business Development in Europe, added further "While we are expanding our pipeline with generic peptides, GalNAc and oligonucleotides, we're also signing CRDMO contracts for new modalities with innovators.